Based on our data demonstrating that overexpression of eEF1A2 stimulates utrophin A protein expression in skeletal muscle of wild-type and mdx mice, we sought to identify FDA-approved drugs that target eEF1A2 to activate utrophin A translation as a therapeutic approach for treating DMD. This evidence concerns the gene EEF1A2 and Duchenne muscular dystrophy.